Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06485258 · ClinicalTrials.gov registry record · Phase 1
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
A Phase 1 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT06485258 is a Phase 1 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 50 participants.
The verdict
NCT06485258, a Phase 1 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) for intramuscular administration (IM) in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Interventions
- OTHER Placebo
- BIOLOGICAL 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
- BIOLOGICAL 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2026-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06485258
The ClinicalTrials.gov registry entry for NCT06485258 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06485258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06485258 about?
NCT06485258 is a clinical study titled "CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults". This is a study of CDC-9 inactivated rotavirus vaccine (IRV) for intramuscular administration (IM) in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
What is the current status of trial NCT06485258?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-08-06. Estimated completion is 2026-02-04.
What interventions are being tested in trial NCT06485258?
The interventions under investigation include: Placebo (OTHER), 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV) (BIOLOGICAL), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06485258?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.